News - Appointments

James Phillips, a physician and biopharma executive, is to become chief executive of Paion AG on 16 October succeeding the company’s co-founder and CEO Wolfgang Söhngen who is retiring.

The regulatory consultancy NDA Group has appointed Robert Kronqvist as general manager for its Nordic affiliate headquartered in Stockholm, to help biotech companies bring their products through registration and onto the market.

Klaas Bakker, a former executive at AstraZeneca Plc, is to join Oncopeptides AB as chief medical officer in November to help the company manage a global, confirmatory Phase 3 trial of its peptide conjugate melflufen for multiple myeloma.

The Belgian immunotherapy company iTeos Therapeutics SA has appointed Matthew Call as chief operating officer to guide business development as its cancer drugs progress through the clinic. iTeos’ lead programme is an adenosine A2A receptor antagonist in Phase 1 for advanced cancer.

Circassia Pharmaceuticals Plc has appointed the former Pfizer Inc executive Jonathan Emms to the newly created role of chief operating officer to lead the commercialisation of the company’s respiratory products.

Karus Therapeutics Ltd, a British biotech developing small molecules for cancer, has appointed Hilary McElwaine-Johnn to the position of chief medical officer. Dr McElwaine-Johnn is a physician with more than 25 years of experience in drug development.

Domain Therapeutics SA of Strasbourg, France has appointed Xavier Leroy to the position of chief technology officer (CTO) to drive development of the company’s G protein-coupled receptor (GPCR) drug discovery platform.

PhoreMost Ltd, a 2015 spin-out from Cambridge University with technology for identifying new drug targets, has appointed Lorenz Mayr to its board as a non-executive director.

Patrick Tricoli has become global head of business development at Nanobiotix SA following a corporate reorganisation which also saw Edwina Baskin-Bey become chief medical officer and Elsa Borghi head of drug discovery.

UK entrepreneur John Burt has been named chief executive of Medherant Ltd, a company with a clinical-stage transdermal patch for the treatment of pain.